Celyad Oncology S.A.
CLYYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $14 | $172 | $14 | $58 |
| % Growth | -91.9% | 1,128.6% | -75.9% | – |
| Cost of Goods Sold | $212 | $224 | $9 | $25 |
| Gross Profit | -$198 | -$52 | $5 | $33 |
| % Margin | -1,414.3% | -30.2% | 35.7% | 56.9% |
| R&D Expenses | $2,100 | $1,776 | $1,537 | $2,529 |
| G&A Expenses | $1,700 | $1,351 | $1,737 | $2,218 |
| SG&A Expenses | $1,700 | $1,461 | $1,737 | $2,320 |
| Sales & Mktg Exp. | $0 | $78 | $0 | $83 |
| Other Operating Expenses | -$100 | -$299 | -$186 | -$104 |
| Operating Expenses | $3,700 | $2,938 | $3,088 | $4,745 |
| Operating Income | -$3,700 | -$2,990 | -$3,083 | -$4,712 |
| % Margin | -26,428.6% | -1,738.4% | -22,021.4% | -8,124.1% |
| Other Income/Exp. Net | $76 | $109 | $4 | -$59 |
| Pre-Tax Income | -$3,700 | -$2,881 | -$3,079 | -$4,771 |
| Tax Expense | $0 | -$102 | $0 | -$85 |
| Net Income | -$3,700 | -$2,779 | -$3,044 | -$4,708 |
| % Margin | -26,428.6% | -1,615.7% | -21,742.9% | -8,117.2% |
| EPS | -0.089 | -0.067 | -0.12 | -0.16 |
| % Growth | -33.2% | 44.1% | 25% | – |
| EPS Diluted | -0.089 | -0.067 | -0.12 | -0.16 |
| Weighted Avg Shares Out | 41,400 | 41,429 | 25,722 | 28,850 |
| Weighted Avg Shares Out Dil | 41,400 | 41,429 | 25,722 | 28,850 |
| Supplemental Information | – | – | – | – |
| Interest Income | $22 | $53 | $100 | $4 |
| Interest Expense | $42 | $58 | $61 | $63 |
| Depreciation & Amortization | $92 | $221 | $229 | $236 |
| EBITDA | -$3,609 | -$2,602 | -$2,789 | -$4,468 |
| % Margin | -25,775% | -1,512.8% | -19,921.4% | -7,703.4% |